Medindia

X

HeartWare to Present at Bank of America Merrill Lynch Health Care Conference in New York

Friday, May 7, 2010 Press Release J E 4
Advertisement


FRAMINGHAM, Mass. and SYDNEY, May 6 HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it is scheduled to make an investor presentation at the Bank of America Merrill Lynch Health Care Conference at 4:20 p.m. EDT on Tuesday, May 11. The conference will be held May 11-13 at the Grand Hyatt Hotel in New York City.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com. An archived replay of the presentation will also be available shortly after the presentation time for a period of 14 days.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD(TM) pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the need for abdominal surgery. HeartWare has received CE Marking for the HeartWare System in the European Union. The device is currently the subject of a United States clinical trial for a bridge-to-transplant indication. For additional information, please visit the company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information: Christopher Taylor HeartWare International, Inc. Email: ctaylor@heartwareinc.com Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
ThermoGenesis Reports Fiscal 2010 Third Quarter Re...
S
Amicus Therapeutics Announces First Quarter 2010 F...